118 related articles for article (PubMed ID: 36181992)
1. The Effect of Stereotactic Body Radiation Therapy for Hepatocellular Cancer on Regional Hepatic Liver Function.
Wei L; Simeth J; Aryal MP; Matuszak M; Haken RKT; Cuneo K; Lawrence TS; Cao Y
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):794-802. PubMed ID: 36181992
[TBL] [Abstract][Full Text] [Related]
2. Deep learning prediction of post-SBRT liver function changes and NTCP modeling in hepatocellular carcinoma based on DGAE-MRI.
Wei L; Aryal MP; Cuneo K; Matuszak M; Lawrence TS; Ten Haken RK; Cao Y; Naqa IE
Med Phys; 2023 Sep; 50(9):5597-5608. PubMed ID: 36988423
[TBL] [Abstract][Full Text] [Related]
3. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.
Nakamura Y; Kimura T; Higaki T; Honda Y; Komoto D; Yamagami T; Iida M; Nagata Y; Honda Y; Aikata H; Chayama K; Awai K
Jpn J Radiol; 2015 Oct; 33(10):627-35. PubMed ID: 26227061
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
6. Hepatic reaction dose for parenchymal changes on Gd-EOB-DTPA-enhanced magnetic resonance images after stereotactic body radiation therapy for hepatocellular carcinoma.
Jung J; Yoon SM; Cho B; Choi YE; Kwak J; Kim SY; Lee SW; Ahn SD; Choi EK; Kim JH
J Med Imaging Radiat Oncol; 2016 Feb; 60(1):96-101. PubMed ID: 26503671
[TBL] [Abstract][Full Text] [Related]
7. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
Sanuki N; Takeda A; Oku Y; Mizuno T; Aoki Y; Eriguchi T; Iwabuchi S; Kunieda E
Acta Oncol; 2014 Mar; 53(3):399-404. PubMed ID: 23962244
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
10. Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study.
Kim N; Cheng J; Huang WY; Kimura T; Zeng ZC; Lee VHF; Kay CS; Seong J
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):464-473. PubMed ID: 33229165
[TBL] [Abstract][Full Text] [Related]
11. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
[TBL] [Abstract][Full Text] [Related]
12. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
Eriguchi T; Takeda A; Sanuki N; Oku Y; Aoki Y; Shigematsu N; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1006-11. PubMed ID: 23102838
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.
Lazarev S; Hardy-Abeloos C; Factor O; Rosenzweig K; Buckstein M
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2077-2083. PubMed ID: 30088143
[TBL] [Abstract][Full Text] [Related]
15. Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma.
Dreher C; Høyer KI; Fode MM; Habermehl D; Combs SE; Høyer M
Acta Oncol; 2016 Jul; 55(7):886-91. PubMed ID: 26878669
[TBL] [Abstract][Full Text] [Related]
16. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.
Qiu H; Moravan MJ; Milano MT; Usuki KY; Katz AW
J Gastrointest Cancer; 2018 Dec; 49(4):463-469. PubMed ID: 28710606
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma.
Park S; Jung J; Cho B; Kim SY; Yun SC; Lim YS; Lee HC; Park J; Park JH; Kim JH; Yoon SM
J Gastroenterol Hepatol; 2020 Nov; 35(11):1953-1959. PubMed ID: 32052884
[TBL] [Abstract][Full Text] [Related]
18. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
19. Gadoxetic Acid Uptake Rate as a Measure of Global and Regional Liver Function as Compared With Indocyanine Green Retention, Albumin-Bilirubin Score, and Portal Venous Perfusion.
Simeth J; Aryal M; Owen D; Cuneo K; Lawrence TS; Cao Y
Adv Radiat Oncol; 2022; 7(5):100942. PubMed ID: 35496263
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
